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IV to PO Conversion of Antimicrobials: Small Intervention, Big Impact
Wenjing Wei, PharmD October 4, 2018: 12:30 PM Background. Appropriate conversions from intravenous (IV) to oral (PO) therapy early in the hospital stay can promote patient comfort and satisfaction while decreasing unnecessary costs and adverse events related to IV catheters. Although IV to PO conversion as a stewardship intervention is considered "low hanging fruit," the time spent on review can be extensive and reporting can be challenging. Utilization of an automated decision support system allows for easy monitoring of IV to PO switches as well as identification of ways to enhance the efficiency and effectiveness of the program. The primary objective was improving IV to PO conversions through an automated system and measuring outcomes electronically without manual chart review. Desired metrics were percentage of eligible antimicrobials ordered as PO, number of conversions, and cost avoidance.
Methods. A protocol was approved by the Pharmacy and Therapeutics committee allowing pharmacists to auto-convert medications from IV to PO when meeting prespecified criteria. These identification criteria were implemented electronically using a traffic light decision support system to prioritize eligible patients (Figure 1) . Education was provided both in person and as pocket cards with guidance on eligible antimicrobials for IV to PO conversions. Metrics were based on monthly antimicrobial utilization data and displayed as a dashboard (Figure 2) .
Results. Monthly metrics provided the stewardship team feedback on the effectiveness of the IV to PO program and identified areas for improvement. From January 2017 to January 2018, cost avoidance from ordering PO as opposed to IV agents was $524,788 with 1,843 IV to PO conversions performed by both providers and pharmacists. A total of 65% of the eligible antimicrobials were ordered via the PO route. Based on these findings, a multifaceted approach to further expand the initiative was undertaken.
Conclusion. The IV to PO decision support system improves the efficiency of IV to PO review process and reduces time spent reviewing charts of patients who do not meet criteria for conversion. The development of automated monthly metrics is an efficient method to assess the effectiveness of the program as well as identify key areas for future development. Background. Prospective audit and feedback is one of the core strategies of an antimicrobial stewardship program (ASP). Here, we hypothesized that the addition of AIR to our extant ASP would enhance appropriate use of parenteral (IV) antibiotics (ABs) on a large inpatient medical service.
Methods. Adult patients on medicine wards beginning in October 2017 and not followed by the infectious diseases (ID) service were included for stewardship intervention if they were on IV ABs ≥48 hours. Recommendations were classified into: (1) duration of therapy; (2) dose adjustment; (3) IV to oral conversion; (4) adverse event prevention; (5) AB avoidance; (6) anti-pseudomonal or (7) vancomycin de-escalation; (8) AB discontinuation; (9) ID consult; (10) Δ alternative AB; (11) allergy assessment; or (12) diagnostics. Early impact of the interventions was assessed after 3 months via the Standardized Antimicrobial Administration Ratio (SAAR) and compared with the 3-month, pre-AIR period. The SAAR is used to benchmark facilities' AB use against those of similar complexity; SAAR = 1 indicates that observed = predicted use.
Results. For 158 interventions made, the most common syndromes were pneumonia (41%), skin and soft tissue (29.4%), and urinary tract infection (17.7%). Intervention categories other than 4, 9, and 11 had acceptance rates >85% (Figure 1 Conclusion. The majority of AB use recommendations delivered by a pharmacist-physician stewardship team were highly accepted by medical providers and led to a 15-20% decrease in overall AB use, without adverse effect during the immediate postintervention period. Potential clinical benefits, such as decreased rates of Clostridium difficile disease, will need to be measured as the AIR program advances. It is worth noting that interventions for AB allergy assessment were least accepted by providers, possibly due to time required to comply. Design of prospective audit and feedback programs may need to address this potential deficiency. Background. The use of fluoroquinolones, one of the most commonly used antibiotic classes in the United States, is associated with adverse drug events, Clostridium difficile infection and antibiotic resistance in Staphylococcus aureus and other Gramnegative bacilli. Many hospitals have instituted resource-intensive interventions to minimize fluoroquinolone use. In hospital settings with fewer resources, education and awareness campaigns offer a more feasible approach. The purpose of this study was to assess the impact of a nonrestrictive fluoroquinolone reduction initiative on institutional antibiotic resistance.
Disclosures
Methods. This is a retrospective pre-and postinterventional ecological study. The fluoroquinolone reduction initiative consisted of house staff education on risks of fluoroquinolone use and alternatives. Buttons promoting "Save the Quinolones" were also distributed and worn to increase visibility. The preintervention period and postintervention periods were February 2016 to December 2016 and February 2017 to December 2017, respectively. The primary outcome measure was the percentage of S. aureus susceptible to oxacillin isolated before and after the intervention. Secondary outcome measures were the rate of fluoroquinolone use, and the percentages of Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, and Pseudomonas aeruginosa susceptible to levofloxacin. Antibiotic use data were collected as inpatient intravenous antibiotic days of therapy per 1,000 patient-days (DOT/1,000 patient-days). Chisquare test was used to compare outcomes.
Results. In the post intervention period, fluoroquinolone use decreased from 75 to 40.1 DOT/1,000 patient-days (−34.9, 95% CI −37.3 to −32.5, P < 0.001). S. aureus susceptibility to oxacillin increased from 47.2% to 55.2% (difference 8.0, 95% CI 1.2 to 14.7, P = 0.02). P. aeruginosa susceptibility to levofloxacin increased from 60% to 70.7% (difference 10.7, 95% CI 0.8 to 20.6, P = 0.04). No difference in susceptibility rates of E. coli, P. mirabilis or K. pneumoniae was detected.
Conclusion. A nonrestrictive fluoroquinolone reduction initiative led to a significant decrease in fluoroquinolone use. This was associated with decreased antibiotic resistance in S. aureus and P. aeruginosa.
Disclosures. All authors: No reported disclosures. Background. Fluoroquinolones have been associated with severe and even disabling side effects. Increasing resistance has rendered these agents less favorable for empiric therapy. In light of these concerns and in response to a period of above-average use at a small community-based academic hospital, we implemented a quality improvement initiative to reduce utilization of ciprofloxacin.
The Impact of Education and Prospective
Methods. The multidisciplinary Antibiotic Stewardship Program (ASP) at Barnes-Jewish West County Hospital, a 77-bed facility, developed and disseminated guidelines for ciprofloxacin use to all physicians via an electronic newsletter and in-person meetings with provider groups identified as having high ciprofloxacin utilization rates beginning in June 2017. Included in the guidelines were recommendations for more effective, safer alternatives to ciprofloxacin for common infection types. In December 2017, the ASP pharmacist initiated prospective audit and feedback (PAF) for all ciprofloxacin orders. Ciprofloxacin utilization was measured monthly in days of therapy (DOT)/1,000 patient-days utilizing medication administration data. Patient days were determined according to National Healthcare Safety Network (NHSN) conventions.
Results. During the preintervention period (June 2015 to June 2017), ciprofloxacin utilization rates averaged 73.3 DOT/1,000 patient-days, but in May 2017, use increased to 138.3. Following provider education, average utilization decreased to 56.9 DOT/1,000 patient-days from September 2017 to November 2017. With the addition of PAF, average ciprofloxacin utilization decreased to 43.6 DOT/1,000 patient-days from December 2017 to March 2018, a 41% reduction compared with the preintervention period. Utilization of other fluoroquinolones did not increase.
Conclusion. Education was a useful tool in reducing inappropriate ciprofloxacin use; however, a combination of prospective audit and feedback with education achieved the greatest impact on curbing ciprofloxacin use. This multimodal approach was effective and sustainable at a small hospital with limited antibiotic stewardship resources.
Disclosures. J. G. Newland, Merck: Grant Investigator, Research grant. Background. Recommended strategies for antimicrobial stewardship (AMS) include prospective audit with feedback (PAF) and preauthorization (PA). Depending on hospital culture, initiation of PA can be difficult. The impact of various single AMS strategies on antibiotic consumption has been described, although the impact of several strategies over time has not been reported.
Impact of Different Stewardship
Methods. At an academic institution, the impact of various AMS strategies on daptomycin utilization was evaluated over time. A progression of four different approaches was used for restriction: Period 1 (P1): September 2012-June 2013-PAF. Period 2 (P2): July 2013-January 2016-8-day automatic stop. Period 3 (P3): February 2016-December 2017-3-day automatic stop, PA for >3-day use required. Period 4 (P4): January 2018-May 2018-PA. Transition to each strategy was supported by a policy change, approved through the Pharmacy and Therapeutics Committee and Hospital Medical Board. During P1-3, reserved medication orders were reviewed daily by AMS with recommended interventions when appropriate and providers were notified of pre-set stop dates (P2-3). During P4, ordering providers were required to
